Patents Assigned to ONO
  • BISPECIFIC ANTIBODY
    Publication number: 20240287187
    Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
    Type: Application
    Filed: April 30, 2024
    Publication date: August 29, 2024
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Takuya Shimbo, Tomoya Tezuka, Mark Throsby, Cornelis Adriaan DE Kruif, Pieter Fokko van Loo, Rinse Klooster
  • SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS
    Publication number: 20240270755
    Abstract: A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6: in which all symbols represent the same meaning as the symbols described in the specification.
    Type: Application
    Filed: April 8, 2024
    Publication date: August 15, 2024
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi Yoshida, Ryuichi Hyakutake, Nozomu Nagashima, Ryosuke Misu, Shohei Mori
  • CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY
    Publication number: 20240254226
    Abstract: An effective cancer treatment method is disclosed. According to the cancer treatment method, a CD47 inhibitory substance, an immune checkpoint inhibitory substance (for example, an anti-PD-1 antibody), and a standard therapy (for example, a combination therapy in which Bevacizumab or Cetuximab is added to FOLFOX therapy for radically unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a dose-reduced regimen thereof for pancreatic cancer having distant metastasis) are combined. The treatment method is useful for cancer treatment.
    Type: Application
    Filed: June 9, 2022
    Publication date: August 1, 2024
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: Tatsuya OKAMOTO
  • Compounds having S1P5 receptor agonistic activity
    Patent number: 12049445
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Grant
    Filed: November 8, 2021
    Date of Patent: July 30, 2024
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide Watanabe, Kensuke Kusumi, Satomi Imaide, Toshimitsu Endo, Takaki Komiya, Naomi Tsuburaya
  • Pharmaceutical composition for treating tumor
    Patent number: 12036204
    Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: July 16, 2024
    Assignees: EISAI R&D MANAGEMENT CO., LTD., ONO PHARMACEUTICAL CO., LTD.
    Inventors: Taro Semba, Yasuhiro Funahashi, Takuya Suzuki
  • THERAPEUTIC AGENT FOR SOLID CANCERS, WHICH COMPRISES AXL INHIBITOR AS ACTIVE INGREDIENT
    Publication number: 20240189300
    Abstract: A therapeutic agent for solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt and to be administered in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination has strong antitumor effect and is therefore useful for treatment of solid cancers.
    Type: Application
    Filed: October 18, 2023
    Publication date: June 13, 2024
    Applicants: ONO PHARMACEUTICAL CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Koichi TAKAYAMA, Tadaaki Yamada, Tomoko Yasuhiro, Kohei Tanaka
  • INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION
    Publication number: 20240190824
    Abstract: Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 13, 2024
    Applicants: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W LINDSLEY, Darren W ENGERS, Elizabeth S CHILDRESS, Sean R BOLLINGER, Joza SCHMITT, Trevor C CHOPKO, Jerod S DENTON, Motoyuki TANAKA, Haruto KURATA
  • MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION
    Publication number: 20240182445
    Abstract: Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to prevent and/or treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 6, 2024
    Applicants: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W LINDSLEY, Darren W ENGERS, Elizabeth S CHILDRESS, Sean R BOLLINGER, Joza SCHMITT, Aaron T GARRISON, Charles K PERRY, Jerod S DENTON, Motoyuki TANAKA
  • HER2 targeting agent
    Patent number: 11981747
    Abstract: An antibody or antigen-binding fragment thereof is disclosed. The antibody or antigen-binding fragment thereof binds to HER2 expressed on a cancer cell or a fragment of the HER2. A HER2-targeting agent containing any of the antibody or antigen-binding fragment thereof, and a pharmaceutical composition containing the HER2-targeting agent are disclosed.
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: May 14, 2024
    Assignees: ONO PHARMACEUTICAL CO., LTD., TOHOKU UNIVERSITY
    Inventors: Yukinari Kato, Mika Kaneko, Daisuke Nakayama, Masayuki Kurogi
  • Substituted cyclopenta[c]pyrroles as ABHD6 antagonists
    Patent number: 11981682
    Abstract: A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6: in which all symbols represent the same meaning as the symbols described in the specification.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: May 14, 2024
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi Yoshida, Ryuichi Hyakutake, Nozomu Nagashima, Ryosuke Misu, Shohei Mori
  • PURINONE DERIVATIVE
    Publication number: 20240083899
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: July 3, 2023
    Publication date: March 14, 2024
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Sting agonistic compound
    Patent number: 11919917
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: March 5, 2024
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke Hanada, Masaya Kokubo, Masakuni Kurono, Kenichi Kouda, Hiroshi Hagiya
  • HMGN partial peptide and cancer therapy using the same
    Patent number: 11919932
    Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: January 3, 2023
    Date of Patent: March 5, 2024
    Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
  • Purinone derivative hydrochloride
    Patent number: 11897885
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: February 13, 2024
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • ABHD6 ANTAGONIST
    Publication number: 20240010658
    Abstract: A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6: in which all symbols represent the same meaning as the symbols described in the specification.
    Type: Application
    Filed: September 22, 2023
    Publication date: January 11, 2024
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi YOSHIDA, Ryuichi HYAKUTAKE, Nozomu NAGASHIMA, Ryosuke MISU, Shohei MORI
  • HER2 TARGETING AGENT
    Publication number: 20240002531
    Abstract: An antibody that binds to HER2 expressed on a cancer cell or a fragment of the HER2, or an antigen binding fragment thereof are disclosed. Uses of the antibody or antigen binding fragment thereof are disclosed. The antibody or antigen binding fragment thereof is useful to target a HER2 expressing cancer cells. A-pharmaceutical composition containing the antibody or antigen binding fragment thereof is also disclosed.
    Type: Application
    Filed: November 29, 2021
    Publication date: January 4, 2024
    Applicants: ONO PHARMACEUTICAL CO., LTD., TOHOKU UNIVERSITY
    Inventors: Yukinari KATO, Mika KANEKO, Daisuke NAKAYAMA, Masayuki KUROGI
  • Activator of TREK (TWIK RElated Kchannels) channels
    Patent number: 11851428
    Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: December 26, 2023
    Assignees: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W. Lindsley, Joshua M. Wieting, Kevin M. Mcgowan, Jerod S. Denton, Kentaro Yashiro, Haruto Kurata, Yoko Sekioka, Takahiro Mori, Yuzo Iwaki
  • CANCER TREATMENT BY COMBINATION OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20230390303
    Abstract: The object of the present invention is to provide an effective method for treating cancer. Provided is a method for treating cancer including a combination of a standard therapy, an EP4 antagonist and an immune checkpoint inhibitor (for example, an anti-PD-1 antibody). The therapeutic method of the present invention is useful for cancer treatment.
    Type: Application
    Filed: November 12, 2021
    Publication date: December 7, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: Maki KONDO
  • Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
    Patent number: 11826363
    Abstract: A therapeutic agent for treatment of solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention has strong antitumor effect and is therefore useful for treatment of solid cancers.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 28, 2023
    Assignees: ONO PHARMACEUTICAL CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Koichi Takayama, Tadaaki Yamada, Tomoko Yasuhiro, Kohei Tanaka
  • STING AGONISTIC COMPOUND
    Publication number: 20230339992
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: June 22, 2023
    Publication date: October 26, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA